Tarsus Pharmaceuticals Inc (TARS)
$74.05
$-0.19
(-0.26%)
As on 01-Sep-2026 16:00EDT
Market cap
$3,149 Mln
Revenue (TTM)
$606 Mln
P/E Ratio
--
P/B Ratio
9.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
43,882,996
6 Years Aggregate
CFO
$-188.77 Mln
EBITDA
$-244.17 Mln
Net Profit
$-244.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| -9.6 | 25.4 | 24.7 | 26.4 | 61.7 | 22.8 | -- |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| 47.9 | 171.2 | 38.1 | -34.8 | -45.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
74.1 | 3,149.0 | 606.3 | -46.5 | -6.2 | -13.5 | -- | 9.1 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for... the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Read more
-
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
-
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
-
Headquarters
Irvine, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tarsus Pharmaceuticals Inc (TARS)
What is the current share price of Tarsus Pharmaceuticals Inc (TARS) Today?
The share price of Tarsus Pharmaceuticals Inc (TARS) is $74.05 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Tarsus Pharmaceuticals Inc (TARS) has given a return of 61.71% in the last 3 years.
What is the current PB & PE ratio of Tarsus Pharmaceuticals Inc (TARS)?
Since, TTM earnings of Tarsus Pharmaceuticals Inc (TARS) is negative, P/E ratio is not available.
The P/B ratio of Tarsus Pharmaceuticals Inc (TARS) is 9.11 times as on 28-Aug-2026, a 76 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-52.74 |
10.20 |
2024 |
-18.48 |
9.51 |
2023 |
-4.76 |
3.28 |
2022 |
-6.06 |
1.95 |
2021 |
-33.57 |
2.78 |
What is the 52 Week High and Low of Tarsus Pharmaceuticals Inc (TARS)?
The 52-week high and low of Tarsus Pharmaceuticals Inc (TARS) are Rs 85.25 and Rs 48.20 as of 02-Sep-2026.
What is the market cap of Tarsus Pharmaceuticals Inc (TARS)?
Tarsus Pharmaceuticals Inc (TARS) has a market capitalisation of $ 3,149 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Tarsus Pharmaceuticals Inc (TARS)?
Before investing in Tarsus Pharmaceuticals Inc (TARS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.